✦ LIBER ✦

Treatment with alendronate prevents fractures in women with postmenopausal osteoporosis

✍ Scribed by S. T. Harris; N. B. Watts; D. Hosking; S. Adami; H. Quan; D. Shapiro; D. E. Thompson; A. C. Santora; D. B. Karpf

Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 142 KB
Volume: 6
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf02500582

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First fractures among postmenopausal wom

First fractures among postmenopausal women with osteoporosis

✍ Angelina Sontag; John H. Krege 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 157 KB

Prevention of vertebral fractures by str

Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis

✍ Juliet Compston 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 155 KB

Alendronate reduced vertebral fracture r

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

✍ Kazuhiro Kushida; Masataka Shiraki; Toshitaka Nakamura; Hideaki Kishimoto; Hirot 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 120 KB

Alendronate reduced vertebral fracture r

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

✍ Kazuhiro Kushida; Masataka Shiraki; Toshitaka Nakamura; Hideaki Kishimoto; Hirot 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 468 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

The effects of 7 years of risedronate treatment were evaluated in a second 2-year extension of a 3-year vertebral fracture study in women with osteoporosis. For the first 5 years of the study, women received risedronate 5 mg/day or placebo according to the original randomization, with maintenance of